Bain Capital Life Sciences Investors, LLC

CIK 0001703031 · BOSTON, MA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source

Bain Capital Life Sciences Investors, LLC reported 21 positions worth $1.68B as of June 30, 2026 (13F filed August 14, 2026). Largest holding: KLRA (29.6%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$1.68B
2026 Q2
Positions
21
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
87.9%
Est. Net Flow (Q)
2026 Q2
10 / 21 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1KLRAKAILERA THERAPEUTICS INCSH$497.5M29.58%22,583,268
2HTFLHEARTFLOW INCSH$247.9M14.74%8,448,158
3NAMSNEWAMSTERDAM PHARMA COMPANYSH$129.0M7.67%3,806,566
4SVRASAVARA INCSH$108.4M6.45%17,600,621
5ALKSALKERMES PLCSH$101.5M6.04%1,937,938
6SLDBSOLID BIOSCIENCES INCSH$98.0M5.83%9,808,819
7PHVSPHARVARIS N VSH$92.5M5.50%2,675,509
8OLMAOLEMA PHARMACEUTICALS INCSH$88.6M5.27%7,085,249
9COAGHEMAB THERAPEUTICS HOLDINGS INCSH$60.6M3.60%1,650,000
10CABACABALETTA BIO INCSH$53.6M3.19%17,241,445

The free plan shows the top 10 positions. The remaining 11 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Bain Capital Life Sciences Investors, LLC hold as of Q2 2026?

Bain Capital Life Sciences Investors, LLC reported 21 positions worth $1.68B in its Q2 2026 13F filing. Largest positions: KLRA (29.6%), HTFL (14.7%), NAMS (7.7%), SVRA (6.4%) and ALKS (6.0%).

What did Bain Capital Life Sciences Investors, LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Bain Capital Life Sciences Investors, LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.